Journal
JOURNAL OF INTERNAL MEDICINE
Volume 247, Issue 4, Pages 485-492Publisher
BLACKWELL SCIENCE LTD
DOI: 10.1046/j.1365-2796.2000.00668.x
Keywords
AGE; amyloid; amyloidosis; FAP; TTR
Categories
Ask authors/readers for more resources
Objectives. Advanced glycation end products (AGE) are present in amyloid deposits in beta(2)-microglobulin amyloidosis, and it has been postulated that glycation of beta(2)-microglobulin may be involved in fibril formation. The aim of this paper was to ascertain whether AGE occur in amyloid deposits in familial amyloidotic polyneuropathy (FAP). Setting. Department of Medicine, Umea University Hospital and First Department of Internal Medicine, Kumamoto University School of Medicine. Design. The presence of AGE was sought immunohistochemically and biochemically in amyloid-rich tissues from patients with FAP. Subjects. Biopsy specimens from nine patients and 10 controls were used for the immunohistochemical analysis. For amyloid preparation, vitreous samples from three FAP patients were used. Results. Immunohistochemical studies using a polyclonal anti-AGE antibody revealed positive immunoreactivity in intestinal materials, but the pattern of reactivity was unevenly distributed; it was often present in the border of amyloid deposits, or surrounding them. Non-amyloid associated immunoreactivity was also observed in a few regions of the specimens, although the AGE-positive structures were situated in areas containing amyloid deposits. Western blotting of purified amyloid from the vitreous body of FAP patients revealed a significant association of AGE with amyloid fibrils. Conclusions. The immunoreactivity for the AGE antibody suggests that AGE may be involved in fibril formation in FAP.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available